<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36735376</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-3450</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the American Society of Nephrology : JASN</Title><ISOAbbreviation>J Am Soc Nephrol</ISOAbbreviation></Journal><ArticleTitle>ADAMTS7-Mediated Complement Factor H Degradation Potentiates Complement Activation to Contributing to Renal Injuries.</ArticleTitle><Pagination><StartPage>291</StartPage><EndPage>308</EndPage><MedlinePgn>291-308</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1681/ASN.0000000000000004</ELocationID><Abstract><AbstractText Label="BACKGROUND">The dysfunction of complement factor H (CFH), the main soluble complement negative regulator, potentiates various complement-induced renal injuries. However, insights into the underlying mechanism of CFH dysfunction remain limited. In this study, we investigated whether extracellular protease-mediated degradation accounts for CFH dysfunction in complement-mediated renal injuries.</AbstractText><AbstractText Label="METHODS">An unbiased interactome of lupus mice kidneys identified CFH-binding protease. In vitro cleavage assay clarified CFH degradation. Pristane-induced SLE or renal ischemia-reperfusion (I/R) injury models were used in wild-type and ADAMTS7-/- mice.</AbstractText><AbstractText Label="RESULTS">We identified the metalloprotease ADAMTS7 as a CFH-binding protein in lupus kidneys. Moreover, the upregulation of ADAMTS7 correlated with CFH reduction in both lupus mice and patients. Mechanistically, ADAMTS7 is directly bound to CFH complement control protein (CCP) 1-4 domain and degraded CCP 1-7 domain through multiple cleavages. In mice with lupus nephritis or renal I/R injury, ADAMTS7 deficiency alleviated complement activation and related renal pathologies, but without affecting complement-mediated bactericidal activity. Adeno-associated virus-mediated CFH silencing compromised these protective effects of ADAMTS7 knockout against complement-mediated renal injuries in vivo.</AbstractText><AbstractText Label="CONCLUSION">ADAMTS7-mediated CFH degradation potentiates complement activation and related renal injuries. ADAMTS7 would be a promising anticomplement therapeutic target that does not increase bacterial infection risk.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 by the American Society of Nephrology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Zihan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Chenfeng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Institute of Biotechnology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Yiting</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Research Unit of Proteomics &amp; Research and Development of New Drugs of Chinese Academy of Medical Sciences, Beijing Institute of Lifeomics, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Qing-Hua</ForeName><Initials>QH</Initials><AffiliationInfo><Affiliation>Department of Microbiology &amp; Infectious Disease Center, School of Basic Medical Sciences, Peking University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xu-Jie</ForeName><Initials>XJ</Initials><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Soc Nephrol</MedlineTA><NlmUniqueID>9013836</NlmUniqueID><ISSNLinking>1046-6673</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D000071118">ADAMTS7 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-65-4</RegistryNumber><NameOfSubstance UI="D017242">Complement Factor H</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Am Soc Nephrol. 2023 Feb 1;34(2):182-183</RefSource><PMID Version="1">36735370</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071118" MajorTopicYN="N">ADAMTS7 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017242" MajorTopicYN="Y">Complement Factor H</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003167" MajorTopicYN="N">Complement Activation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>P. Xu reports Patents or Royalties: Beijing Proteome Research Center. All remaining authors have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>12</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36735376</ArticleId><ArticleId IdType="pmc">PMC10103097</ArticleId><ArticleId IdType="doi">10.1681/ASN.0000000000000004</ArticleId><ArticleId IdType="pii">00001751-202302000-00015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Parente R, Clark SJ, Inforzato A, Day AJ. Complement factor H in host defense and immune evasion. Cell Mol Life Sci. 2017;74(9):1605-1624. doi:10.1007/s00018-016-2418-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2418-4</ArticleId><ArticleId IdType="pmc">PMC5378756</ArticleId><ArticleId IdType="pubmed">27942748</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragon-Durey MA, Loirat C, Cloarec S, et al. . Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16(2):555-563. doi:10.1681/ASN.2004050380</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2004050380</ArticleId><ArticleId IdType="pubmed">15590760</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanc C, Togarsimalemath SK, Chauvet S, et al. . Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol. 2015;194(11):5129-5138. doi:10.4049/jimmunol.1402770</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1402770</ArticleId><ArticleId IdType="pubmed">25917093</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong EKS, Hallam TM, Brocklebank V, et al. . Functional characterization of rare genetic variants in the N-terminus of complement factor H in aHUS, C3G, and AMD. Front Immunol. 2020;11:602284. doi:10.3389/fimmu.2020.602284</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.602284</ArticleId><ArticleId IdType="pmc">PMC7840601</ArticleId><ArticleId IdType="pubmed">33519811</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders RE, Goodship TH, Zipfel PF, Perkins SJ. An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations. Hum Mutat. 2006;27(1):21-30. doi:10.1002/humu.20268</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.20268</ArticleId><ArticleId IdType="pubmed">16281287</ArticleId></ArticleIdList></Reference><Reference><Citation>Raychaudhuri S, Iartchouk O, Chin K, et al. . A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat Genet. 2011;43(12):1232-1236. doi:10.1038/ng.976</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.976</ArticleId><ArticleId IdType="pmc">PMC3225644</ArticleId><ArticleId IdType="pubmed">22019782</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore I, Strain L, Pappworth I, et al. . Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115(2):379-387. doi:10.1182/blood-2009-05-221549</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-05-221549</ArticleId><ArticleId IdType="pmc">PMC2829859</ArticleId><ArticleId IdType="pubmed">19861685</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodship TH, Pappworth IY, Toth T, et al. . Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol Immunol. 2012;52(3-4):200-206. doi:10.1016/j.molimm.2012.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2012.05.009</ArticleId><ArticleId IdType="pubmed">22721707</ArticleId></ArticleIdList></Reference><Reference><Citation>Makou E, Herbert AP, Barlow PN. Functional anatomy of complement factor H. Biochemistry. 2013;52(23):3949-3962. doi:10.1021/bi4003452</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi4003452</ArticleId><ArticleId IdType="pubmed">23701234</ArticleId></ArticleIdList></Reference><Reference><Citation>Renner B, Tong HH, Laskowski J, et al. . Annexin A2 enhances complement activation by inhibiting factor H. J Immunol. 2016;196(3):1355-1365. doi:10.4049/jimmunol.1500793</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1500793</ArticleId><ArticleId IdType="pmc">PMC4724541</ArticleId><ArticleId IdType="pubmed">26729803</ArticleId></ArticleIdList></Reference><Reference><Citation>Stravalaci M, Davi F, Parente R, et al. . Control of complement activation by the long pentraxin PTX3: implications in age-related macular degeneration. Front Pharmacol. 2020;11:591908. doi:10.3389/fphar.2020.591908</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.591908</ArticleId><ArticleId IdType="pmc">PMC7725797</ArticleId><ArticleId IdType="pubmed">33324220</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang FM, Song D, Pang Y, Song Y, Yu F, Zhao MH. The dysfunctions of complement factor H in lupus nephritis. Lupus. 2016;25(12):1328-1340. doi:10.1177/0961203316642307</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316642307</ArticleId><ArticleId IdType="pubmed">27068115</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang FM, Yu F, Tan Y, Song D, Zhao MH. Serum complement factor H is associated with clinical and pathological activities of patients with lupus nephritis. Rheumatology (Oxford). 2012;51(12):2269-2277. doi:10.1093/rheumatology/kes218</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes218</ArticleId><ArticleId IdType="pubmed">22956549</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurman JM, Ljubanovic D, Royer PA, et al. . Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest. 2006;116(2):357-368. doi:10.1172/jci24521</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci24521</ArticleId><ArticleId IdType="pmc">PMC1352158</ArticleId><ArticleId IdType="pubmed">16444293</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao L, Haas M, Quigg RJ. Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol. 2011;22(2):285-295. doi:10.1681/ASN.2010060647</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2010060647</ArticleId><ArticleId IdType="pmc">PMC3029901</ArticleId><ArticleId IdType="pubmed">21148254</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaum BS, Hannan JP, Herbert AP, Kavanagh D, Uhrin D, Stehle T. Structural basis for sialic acid-mediated self-recognition by complement factor H. Nat Chem Biol. 2015;11(1):77-82. doi:10.1038/nchembio.1696</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1696</ArticleId><ArticleId IdType="pubmed">25402769</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y, Zhao H, Man J, Fu S, Yang L. MMP-9-mediated regulation of hypoxia- reperfusion injury-related neutrophil inflammation in an in vitro proximal tubular cell model. Ren Fail. 2021;43(1):900-910. doi:10.1080/0886022x.2021.1930558</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0886022x.2021.1930558</ArticleId><ArticleId IdType="pmc">PMC8168740</ArticleId><ArticleId IdType="pubmed">34057033</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei R, Gao B, Shih F, et al. . Alterations in urinary collagen peptides in lupus nephritis subjects correlate with renal dysfunction and renal histopathology. Nephrol Dial Transplant. 2017;32(9):1468-1477. doi:10.1093/ndt/gfw446</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfw446</ArticleId><ArticleId IdType="pubmed">28339802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler T, Zhang L, Liu Z, et al. . ADAMTS-7 inhibits re-endothelialization of injured arteries and promotes vascular remodeling through cleavage of thrombospondin-1. Circulation. 2015;131(13):1191-1201. doi:10.1161/circulationaha.114.014072</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.114.014072</ArticleId><ArticleId IdType="pubmed">25712208</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Wang Y, Wang F, et al. . Interaction of uromodulin and complement factor H enhances C3b inactivation. J Cell Mol Med. 2016;20(10):1821-1828. doi:10.1111/jcmm.12872</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.12872</ArticleId><ArticleId IdType="pmc">PMC5020621</ArticleId><ArticleId IdType="pubmed">27113631</ArticleId></ArticleIdList></Reference><Reference><Citation>Li LL, Tan Y, Song D, et al. . Anti-complement factor H autoantibodies may be protective in lupus nephritis. Clin Chim Acta. 2020;508:1-8. doi:10.1016/j.cca.2020.05.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.05.005</ArticleId><ArticleId IdType="pubmed">32387092</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CJ, Kong W, Ilalov K, et al. . ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein. FASEB J. 2006;20(7):988-990. doi:10.1096/fj.05-3877fje</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.05-3877fje</ArticleId><ArticleId IdType="pmc">PMC1483927</ArticleId><ArticleId IdType="pubmed">16585064</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouw RB, Brouwer MC, de Gast M, et al. . Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera. Blood Adv. 2019;3(4):621-632. doi:10.1182/bloodadvances.2018025692</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2018025692</ArticleId><ArticleId IdType="pmc">PMC6391659</ArticleId><ArticleId IdType="pubmed">30804016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang FM, Yu F, Zhao MH. A method of purifying intact complement factor H from human plasma. Protein Expr Purif. 2013;91(2):105-111. doi:10.1016/j.pep.2013.07.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pep.2013.07.014</ArticleId><ArticleId IdType="pubmed">23906520</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikawada E, Lenda DM, Kelley VR. IL-12 deficiency in MRL-Faslpr mice delays nephritis and intrarenal IFN-&#x3b3; expression, and diminishes systemic pathology. J Immunol. 2003;170(7):3915-3925. doi:10.4049/jimmunol.170.7.3915</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.170.7.3915</ArticleId><ArticleId IdType="pubmed">12646661</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenda DM, Stanley ER, Kelley VR. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Faslpr mice. J Immunol. 2004;173(7):4744-4754. doi:10.4049/jimmunol.173.7.4744</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.173.7.4744</ArticleId><ArticleId IdType="pubmed">15383612</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai S, Kitada K, Yamazaki T, et al. . Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice. Nat Med. 2016;22(2):183-193. doi:10.1038/nm.4012</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4012</ArticleId><ArticleId IdType="pubmed">26726878</ArticleId></ArticleIdList></Reference><Reference><Citation>Broekema M, Harmsen MC, Koerts JA, et al. . Determinants of tubular bone marrow-derived cell engraftment after renal ischemia/reperfusion in rats. Kidney Int. 2005;68(6):2572-2581. doi:10.1111/j.1523-1755.2005.00728.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2005.00728.x</ArticleId><ArticleId IdType="pubmed">16316332</ArticleId></ArticleIdList></Reference><Reference><Citation>Leffler J, Bengtsson AA, Blom AM. The complement system in systemic lupus erythematosus: an update. Ann Rheum Dis. 2014;73(9):1601-1606. doi:10.1136/annrheumdis-2014-205287</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-205287</ArticleId><ArticleId IdType="pubmed">24845390</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander JJ, Wang Y, Chang A, et al. . Mouse podocyte complement factor H: the functional analog to human complement receptor 1. J Am Soc Nephrol. 2007;18(4):1157-1166. doi:10.1681/ASN.2006101125</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2006101125</ArticleId><ArticleId IdType="pubmed">17344423</ArticleId></ArticleIdList></Reference><Reference><Citation>Danobeitia JS, Djamali A, Fernandez LA. The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis. Fibrogenesis Tissue Repair. 2014;7(1):16. doi:10.1186/1755-1536-7-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1755-1536-7-16</ArticleId><ArticleId IdType="pmc">PMC4224961</ArticleId><ArticleId IdType="pubmed">25383094</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Zheng J, Bai X, et al. . ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries. Circ Res. 2009;104(5):688-698. doi:10.1161/circresaha.108.188425</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.108.188425</ArticleId><ArticleId IdType="pubmed">19168437</ArticleId></ArticleIdList></Reference><Reference><Citation>Pannu N, Bhatnagar A. Oxidative stress and immune complexes: pathogenic mechanisms in pristane induced murine model of lupus. Immunobiology. 2020;225(1):151871. doi:10.1016/j.imbio.2019.11.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2019.11.006</ArticleId><ArticleId IdType="pubmed">31780314</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlenberg JM, Yalavarthi S, Zhao W, et al. . An essential role of caspase 1 in the induction of murine lupus and its associated vascular damage. Arthritis Rheumatol. 2014;66:152-162. doi:10.1002/art.38225</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38225</ArticleId><ArticleId IdType="pmc">PMC4135431</ArticleId><ArticleId IdType="pubmed">24449582</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazir S, Gadi I, Al-Dabet MM, et al. . Cytoprotective activated protein C averts Nlrp3 inflammasome- induced ischemia-reperfusion injury via mTORC1 inhibition. Blood. 2017;130(24):2664-2677. doi:10.1182/blood-2017-05-782102</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2017-05-782102</ArticleId><ArticleId IdType="pmc">PMC5731086</ArticleId><ArticleId IdType="pubmed">28882883</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke J, Zhao F, Luo Y, Deng F, Wu X. MiR-124 negatively regulated PARP1 to alleviate renal ischemia-reperfusion injury by inhibiting TNF&#x3b1;/RIP1/RIP3 pathway. Int J Biol Sci. 2021;17(8):2099-2111. doi:10.7150/ijbs.58163</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.58163</ArticleId><ArticleId IdType="pmc">PMC8193263</ArticleId><ArticleId IdType="pubmed">34131409</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M, Wang Y, Li L, et al. . Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance. Theranostics. 2021;11(4):1845-1863. doi:10.7150/thno.50905</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.50905</ArticleId><ArticleId IdType="pmc">PMC7778599</ArticleId><ArticleId IdType="pubmed">33408785</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong EKS, Kavanagh D. Diseases of complement dysregulation-an overview. Semin Immunopathol. 2018;40(1):49-64. doi:10.1007/s00281-017-0663-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0663-8</ArticleId><ArticleId IdType="pmc">PMC5794843</ArticleId><ArticleId IdType="pubmed">29327071</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Cano M, Datta S, et al. . Pentraxin 3 recruits complement factor H to protect against oxidative stress-induced complement and inflammasome overactivation. J Pathol. 2016;240(4):495-506. doi:10.1002/path.4811</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.4811</ArticleId><ArticleId IdType="pubmed">27659908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopp A, Hebecker M, Svobodova E, Jozsi M. Factor h: a complement regulator in health and disease, and a mediator of cellular interactions. Biomolecules. 2012;2(1):46-75. doi:10.3390/biom2010046</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom2010046</ArticleId><ArticleId IdType="pmc">PMC4030870</ArticleId><ArticleId IdType="pubmed">24970127</ArticleId></ArticleIdList></Reference><Reference><Citation>Jozsi M, Oppermann M, Lambris JD, Zipfel PF. The C-terminus of complement factor H is essential for host cell protection. Mol Immunol. 2007;44(10):2697-2706. doi:10.1016/j.molimm.2006.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2006.12.001</ArticleId><ArticleId IdType="pmc">PMC2700862</ArticleId><ArticleId IdType="pubmed">17208302</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly MP, Li M, He J, et al. . Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet. 2011;377(9763):383-392. doi:10.1016/s0140-6736(10)61996-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(10)61996-4</ArticleId><ArticleId IdType="pmc">PMC3297116</ArticleId><ArticleId IdType="pubmed">21239051</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Y, Bai X, Zhao Y, et al. . ADAMTS-7 forms a positive feedback loop with TNF-alpha in the pathogenesis of osteoarthritis. Ann Rheum Dis. 2014;73(8):1575-1584. doi:10.1136/annrheumdis-2013-203561</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-203561</ArticleId><ArticleId IdType="pmc">PMC4418017</ArticleId><ArticleId IdType="pubmed">23928557</ArticleId></ArticleIdList></Reference><Reference><Citation>Puy C, Pang J, Reitsma SE, et al. . Cross-talk between the complement pathway and the contact activation system of coagulation: activated factor XI neutralizes complement factor H. J Immunol. 2021;206(8):1784-1792. doi:10.4049/jimmunol.2000398</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2000398</ArticleId><ArticleId IdType="pmc">PMC8030746</ArticleId><ArticleId IdType="pubmed">33811105</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Radin M, Yazdany J, et al. . Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int. 2017;37(8):1249-1255. doi:10.1007/s00296-017-3686-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-017-3686-5</ArticleId><ArticleId IdType="pubmed">28258475</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurnberger J, Philipp T, Witzke O, et al. . Eculizumab for atypical hemolytic- uremic syndrome. N Engl J Med. 2009;360(5):542-544. doi:10.1056/nejmc0808527</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmc0808527</ArticleId><ArticleId IdType="pubmed">19179328</ArticleId></ArticleIdList></Reference><Reference><Citation>Welte T, Arnold F, Kappes J, et al. . Treating C3 glomerulopathy with eculizumab. BMC Nephrol. 2018;19(1):7. doi:10.1186/s12882-017-0802-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-017-0802-4</ArticleId><ArticleId IdType="pmc">PMC5767001</ArticleId><ArticleId IdType="pubmed">29329521</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillmen P, Young NS, Schubert J, et al. . The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233-1243. doi:10.1056/nejmoa061648</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa061648</ArticleId><ArticleId IdType="pubmed">16990386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol. 2018;14(1):26-47. doi:10.1038/nrneph.2017.156</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2017.156</ArticleId><ArticleId IdType="pmc">PMC5805379</ArticleId><ArticleId IdType="pubmed">29199277</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti- complement therapy; from disease to clinical trial. Mol Immunol. 2018;102:89-119. doi:10.1016/j.molimm.2018.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2018.06.008</ArticleId><ArticleId IdType="pubmed">30121124</ArticleId></ArticleIdList></Reference><Reference><Citation>Harder MJ, Anliker M, Hochsmann B, et al. . Comparative analysis of novel complement-targeted inhibitors, MiniFH, and the natural regulators factor H and factor H- like protein 1 reveal functional determinants of complement regulation. J Immunol. 2016;196(2):866-876. doi:10.4049/jimmunol.1501919</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1501919</ArticleId><ArticleId IdType="pmc">PMC4707092</ArticleId><ArticleId IdType="pubmed">26643478</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Invest. 2020;130(5):2152-2163. doi:10.1172/jci136094</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci136094</ArticleId><ArticleId IdType="pmc">PMC7190924</ArticleId><ArticleId IdType="pubmed">32310222</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>